NGM announces new data from NGM707 trial, outlines strategies for candidates

NGM Biopharmaceuticals announced encouraging new data from an ongoing Phase 1 Part 1b study evaluating NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA. NGM Bio also outlined its strategy to evolve clinical development of its product candidates aldafermin and NGM120 to focus on rare conditions characterized by significant unmet need. “Our priorities for 2024 center on directing our efforts and investing our resources as efficiently and effectively as possible toward select development activities that we believe have the greatest potential to deliver nearer-term impact and value creation while being fully aligned with our mission to deliver life-changing medicines for patients with significant unmet needs,” said David Woodhouse, PhD, Chief Executive Officer at NGM Bio. NGM707 in Advanced Solid Tumors: Announced encouraging new findings from the Phase 1 Part 1b dose escalation cohort of the ongoing Phase 1/2 trial evaluating NGM707 in combination with pembrolizumab for the treatment of patients with advanced or metastatic solid tumors. The combination of NGM707 and pembrolizumab was generally well tolerated at all four dose levels of NGM707. The maximum tolerated dose was not reached. Eight of the 37 response-evaluable patients had MSS CRC; two of these MSS CRC patients were among the confirmed PRs, including the patient with a pathological CR, and two had SD. Anti-PD-1/L1 monotherapies have shown low or no benefit in MSS CRC patients. Aldafermin in Primary Sclerosing Cholangitis: Announced planned further development of aldafermin for the treatment of PSC, a rare liver disease that irreparably damages the bile ducts, leading to bile acid dysregulation, which, ultimately, results in serious liver damage. NGM120 in Hyperemesis Gravidarum: Announced potential development of NGM120 for the treatment of hyperemesis gravidarum, subject to the outcome of ongoing discussions with the FDA.